Expand all sections

UB 421

Semzuvolimab

Extended indication Monotherapy in HIV-1 Infected Adults
Therapeutic value No estimate possible yet
Registration phase Clinical trials

Product

Active substance UB 421
Domain Infectious diseases
Reason of inclusion New medicine (specialité)
Main indication HIV
Extended indication Monotherapy in HIV-1 Infected Adults
Proprietary name Semzuvolimab
Manufacturer United Biomedical
Mechanism of action Virus inhibitor
Route of administration Intravenous
Therapeutical formulation Intravenous drip
Budgetting framework Intermural (MSZ)

Registration

Registration route Centralised (EMA)
Submission date 2023
Expected Registration 2024
Registration phase Clinical trials
Additional remarks Primary completion datum fase 3 studie in december 2022.

Therapeutic value

Therapeutic value No estimate possible yet
Frequency of administration 1 times every 2 weeks
Dosage per administration 25 mg/kg
References NCT04406727

Expected patient volume per year

There is currently nothing known about the expected patient volume.

Expected cost per patient per year

There is currently nothing known about the expected cost.

Potential total cost per year

There is currently nothing known about the possible total cost.

Off label use

There is currently nothing known about off label use.

Indication extension

There is currently nothing known about indication extensions.

Other information

There is currently no futher information available.